Stock Information
Kymera Therapeutics Inc (KYMR)
Ticker Symbol: KYMR
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $6,144.45 mil
Piotroski score: 3
PE Ratio: N/A
EPS (TTM): -3.5698
Revenue (TTM): $0.53 M
Dividend Yield: N/A%
ROE: -25.02%
Latest News
-
Canaccord Genuity Initiates Coverage On Kymera Therapeutics with Buy Rating, Announces Price Target of $106
Wed, May 6, 2026 1:45 PM
-
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
Wed, May 6, 2026 7:02 AM
-
Kymera Therapeutics Presented New Preclinical Data For KT-579 Demonstrating Disease-modifying Activity In An Inflammatory Bowel Disease Model, KT-579 Phase 1 Healthy Volunteer Trial Ongoing, With Data Expected In 2H26
Tue, May 5, 2026 7:23 AM
-
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
Tue, May 5, 2026 7:02 AM
-
Kymera Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation
Mon, May 4, 2026 7:13 PM
Key Financials
Financial data not available
